18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Wall Street expects an even bigger rebound for this beaten-down biotech stock.
Overview
There's good news and bad news if you own shares of Alnylam Pharmaceuticals (NASDAQ: ALNY). The good news is that the biotech stock is up around 25% since the end of July. The bad news is that Alnylam is still down 35% year-to-date, even with that rebound. Ouch.
Has Wall Street soured on Alnylam? Not at all. Of the 21 analysts who have rated the stock over the last three months, 18 recommended it as a "buy" or "strong buy." Here's why I think these analysts are right to be bullish about Alnylam.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.